Easywell Biomedicals (1799) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 易威

Easywell Biomedicals (1799) reported revenue of NT$67.7 million for Oct 2026, +128.2% year on year and -51.1% from the previous month. Revenue for Jan–Oct 2026 was NT$845 million (+81.8% year on year).

Year-on-year revenue growth: 10 months in a row. →

In Oct 2026, it ranked No. 91 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$47.6 million24/10Nov 2024 NT$37.6 millionDec 2024 NT$68.4 millionJan 2025 NT$32.2 millionFeb 2025 NT$42.7 million25/02Mar 2025 NT$76.6 millionApr 2025 NT$26 millionMay 2025 NT$34.6 millionJun 2025 NT$48.7 million25/06Jul 2025 NT$38.7 millionAug 2025 NT$59.1 millionSep 2025 NT$76.6 millionOct 2025 NT$29.7 million25/10Nov 2025 NT$65 millionDec 2025 NT$67.5 millionJan 2026 NT$77.4 millionFeb 2026 NT$59.1 million26/02Mar 2026 NT$100.1 millionApr 2026 NT$88.5 millionMay 2026 NT$56.8 millionJun 2026 NT$81.3 million26/06Jul 2026 NT$67.7 millionAug 2026 NT$107.8 millionSep 2026 NT$138.5 millionOct 2026 NT$67.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$67.7 million+128.2%-51.1%
Sep 2026NT$138.5 million+80.6%+28.5%
Aug 2026NT$107.8 million+82.4%+59.2%
Jul 2026NT$67.7 million+74.9%-16.7%
Jun 2026NT$81.3 million+67.0%+42.9%
May 2026NT$56.8 million+64.3%-35.8%
Apr 2026NT$88.5 million+240.4%-11.6%
Mar 2026NT$100.1 million+30.6%+69.3%
Feb 2026NT$59.1 million+38.6%-23.7%
Jan 2026NT$77.4 million+140.2%+14.7%
Dec 2025NT$67.5 million-1.3%+3.8%
Nov 2025NT$65 million+72.9%+119.0%
Oct 2025NT$29.7 million-37.7%-61.3%
Sep 2025NT$76.6 million+14.3%+29.7%
Aug 2025NT$59.1 million+13.5%+52.6%
Jul 2025NT$38.7 million-45.8%-20.5%
Jun 2025NT$48.7 million-20.7%+40.6%
May 2025NT$34.6 million-6.2%+33.0%
Apr 2025NT$26 million+5.6%-66.1%
Mar 2025NT$76.6 million+57.7%+79.6%
Feb 2025NT$42.7 million+199.0%+32.4%
Jan 2025NT$32.2 million+205.2%-52.9%
Dec 2024NT$68.4 million+1.1%+81.9%
Nov 2024NT$37.6 million+451.9%-21.1%
Oct 2024NT$47.6 million+111.1%-28.9%

Jan–Oct 2026 cumulative: NT$845 million (+81.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Easywell Biomedicals vs PEC / Easywell Biomedicals vs Lotus Pharm / Easywell Biomedicals vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

因新藥/學名藥產品出貨較去年同期多,故營收成長。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16